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Adverse Effects of Antidepressants Reported by a Large International 
Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects.  
 
Abstract: 
Background: Studies of the adverse effects of antidepressants tend to focus on biological 
symptoms. The prevalence of suicidality and withdrawal effects are currently a source of 
controversy. 
Objective: To directly ascertain the experiences of an international sample of antidepressant 
users. 
Method: An online survey asked adult antidepressant users whether they had experienced 20 
adverse effects ‘as a result of taking the antidepressant’, and if so, to what degree of severity. 
1,431 people from 38 countries responded.  
Results:  61% of the respondents reported at least ten of the 20 effects, most commonly: 
‘Feeling emotionally numb’ (reported by 71%), ‘Feeling foggy or detached’ (70%); ‘Feeling 
not like myself’ (66%), ‘Sexual difficulties’ (66%), ‘Drowsiness’ (63%),  and ‘Reduction in 
positive feelings’ (60%). ‘Suicidality’ as a result of the drugs was reported by 50%.  
Withdrawal effects were reported by 59%, and ‘Addiction’ by 40%. Rates of adverse effects 
were higher for those prescribed multiple antidepressants and those who also took 
antipsychotics. Younger age and longer use of ADs were positively related to total adverse 
effects. One third did not recall being told about any side effects by the prescriber. Less than 
5% were told about suicidality, emotional numbing, withdrawal effects or addiction.  
Conclusions:  Asking people directly reveals far higher rates of adverse responses to 
antidepressants than previously understood, especially in the emotional, psychological and 
interpersonal domains. Given recent findings that antidepressants are only marginally more 
effective than placebo, the findings of the current study imply a cost-benefit analysis that 
cannot justify the extremely high prescription rates for these drugs.  
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1. INTRODUCTION 
Prescription rates for antidepressants (ADs) are high and increasing [1]. One in eight 
adults in the USA were prescribed ADs by 2012 [2]. In 2016, England had 64.7 million 
prescriptions for a population of 55.3 million. This was double the prescriptions in 2006 and 
means that about one in seven women and one in 13 men are currently receiving 
antidepressants in England [3]. These extraordinary prescription rates are difficult to 
understand in terms of evidence-based cost-benefit analyses. Less than half of trials find ADs 
superior to placebo [4], with properly blinded studies particularly unlikely to find any 
difference to placebo [5, 6]. An early meta-analysis found that ‘the overall effect of new-
generation antidepressant medications is below recommended criteria for clinical 
significance’ [7]. A recent meta-analysis [8] reached much more favorable conclusions but 
the median duration of treatment in the included studies was just eight weeks and studies 
were excluded if 20% or more of the participants were ‘treatment- resistant’ (i.e. it was 
known that the drugs did not work for them) were excluded. Furthermore the meta-analysis 
paid no attention to adverse effects. Another recent, more rigorous, meta-analysis [9], of 131 
placebo-controlled trials, which did include adverse effects, again found that the overall 
effect size does not reach the threshold for ‘clinical significance’ and also found that ADs 
produce significantly more ‘serious’ and non-serious’ adverse effects than placebos. It was 
concluded that ‘The potential small beneficial effects seem to be outweighed harmful effects 
of SSRIs versus placebo for major depressive disorder seem to outweighed by harmful 
effects’ [9]. Of particular relevance to the current study was the finding that ‘There was 
almost no data on suicidal behavior, quality of life and long-term effects’. 
Studies, and checklists, of these harmful effects have indeed focussed on biological or 
medical effects. Of the 84 adverse events reported by the 2017 meta-analysis to have been 
studied at least once, almost all were biological/medical reactions. The eight effects most 
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often assessed in the 131 drug trials were: nausea, headache, dry mouth, insomnia, 
somnolence, diarrhea, dizziness and constipation effects’ [9]. Both the ‘Antidepressant Side-
Effect Checklist’ [10] and the ‘Patient-Rated Inventory of Side Effects (PRISE)’ [11] focus 
almost exclusively on these bio-medical phenomena and fail to address the psychological or 
interpersonal domains (although some, such as sexual impairment, can be seen as both 
biological and interpersonal).  
A 2013 review [12] of the few, relatively small scale, studies of the actual experiences of 
AD users [e.g. 13-17] identified multiple adverse effects relating to quality of life, in the 
psychological, emotional and interpersonal domains. These included emotional detachment, a 
belief that ADs prevent natural sadness, harmful effects on relationships, caring less about 
self and others, fear of addiction, and suicidality. For example of 468 descriptions of adverse 
effects by AD users on a website the most frequent were sedation, impaired cognition, 
reduced libido, emotional blunting, activation (arousal, insomnia, agitation) and 
emotional instability [14]. 
The largest survey of AD users to date [18] identified surprisingly high rates of adverse 
effects among 1,829 New Zealanders, especially in the personal and interpersonal domains. 
These included: Sexual difficulties (62%), Feeling emotionally numb (60%), Feeling not like 
oneself (52%), Agitation (47%), Reduction in positive feelings (42%), Suicidality (39%), and 
Caring less about others (39%). It also identified high rates of Withdrawal effects (55%) and 
Addiction (27%).  
The New Zealand survey reflects the growing interest in the views of ‘experts-by-
experience’ in general and of Patient-Reported Outcome Measures (PROMs) in particular. 
These tools are increasingly recognized as an essential component of the governance of 
healthcare systems and the assessment of drugs, with a particular focus on understanding 
whether health care [19] and mental health care [20] are beneficial and safe. The current 
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study aimed, therefore, to expand our knowledge of the first-hand experience of people who 
take ADs by replicating the New Zealand study with a similarly large, but international, 
sample. 
 
2. METHODS 
2.1  Instrument 
‘The Experiences of Anti-depressant and Anti-psychotic Medication Survey’ was developed 
for this study (https://swinuw.au1.qualtrics.com/jfe/form/SV_0jPOxpXhPLNZjmZ). It was in 
English, with no translations made available. The anti-depressant sections of the 
questionnaire were based on the New Zealand ‘Views on Antidepressants’ questionnaire [18, 
21-23]. The questionnaire generated quantitative (yes/no and multiple-choice questions) and 
qualitative data (open-ended questions), about: the prescribing experience, the positive and 
negative effects of medications, causal beliefs about psychosis/depression, alternative 
treatments, experiences of withdrawing from the medications, and demographics, 
The current paper reports the adverse outcomes of the AD section. Adverse effects were 
assessed with the question ‘Please rate the following side effects you may have experienced 
as a result of taking the anti-depressant’, followed by a list of 20 effects and the options to 
respond to each with ‘Not at all’, ‘Mild’, ‘Moderate’ or ‘Severe’ (see Table 2). Three of the 
20 side effects in the original ‘Views on Antidepressants’ questionnaire were not included; 
two because they were the least frequently endorsed (‘Diarrhoea’ - 20% and ‘Weight loss’ - 
15%), and one, ‘Failure to reach orgasm’, because it was covered by ‘Sexual difficulties’. 
These three were replaced with three new items that had been spontaneously reported by 
numerous participants: ‘Insomnia’, ‘Feeling foggy or detached’, and ‘Distorted dreams’ [18]. 
Participants were also invited to report ‘Other’ side effects. They were further asked (in a 
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Section titled ‘When you were first prescribed anti-depressant’) ‘Did the doctor inform you 
of any possible side effects?’ (Yes/No) and ‘If Yes, what side effects were mentioned?’ 
 
2.2 Participants 
Of the 2,346 people who responded 668 were recruited via an Australian online research 
company, and 1,678 people via advertisements on social media and snowball sampling. Of 
the 2,133 who had taken ADs, 42 were deleted because they ticked ‘no’ when asked to 
confirm that they met the following criteria: ‘I have been taking or have previously taken 
antidepressant medication continuously for at least one month for any reason’; ‘I am aged 18 
or older’; and ‘I am not currently compulsorily detained in a psychiatric hospital’.  
Among the remaining 2,091 responses, the 44 that responded to ‘What is the name of your 
current or most recent anti-depressant medication?’ with a drug that is not an anti-depressant 
were deleted (most commonly valium - 16, xanax - 7 and lithium - 5). There were 39 
responses emanating from the same Internet Protocol (IP) address as another response, 
indicating use of the same computer. Of these 39, 33 were deemed a repeat response by the 
same person (based on identical demographics or very similar responses) and were deleted. 
Of the remaining 2,014, 497 completed the demographics section but very few or no 
questions in the AD section, leaving 1,517. The questions about adverse effects were not 
answered by 86 people. This left 1,431 for the analyses for this paper (see Figure 1).  
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Figure 1. Flowchart of participants. 
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2.3. Data Analysis 
A Total Adverse Effects (TAE) score was calculated by combining the scores (0 - 3) for 
the 20 side effects, producing a potential range of 0 to 60. (There were 57 responses with 
between one and four empty boxes in the adverse effects section and these were scored as 
‘0’- ‘not at all’). The TAE thereby incorporates both the frequency of different adverse 
effects and their severity. Spearman Rank Order Correlation Coefficients (rho) were used to 
test for relationships between dimensional variables, e.g. age and likert scale measures of 
adverse effects. Independent sample, two-tailed t-tests were used to explore differences 
between mean scores in relation to gender, duration of treatment (< 3 years vs > 3 years) and 
types of drug. The level of significance was set at the p < .01 level because of the high 
number of tests and the consequent risk of false positives. 
 
3. RESULTS 
3.1. Sample Characteristics 
Of the 1,517 participants, 1,018 (67.1%) had taken only ADs, and 499 (32.9%) had also 
taken APs. When completing the survey 813 (53.6%) were still taking ADs. Of the 1,497 
who reported how long they had taken APs, 6.2% responded less than three months, 14.7% 
said 3 to 12 months, 16.5% one to three years, and 62.5% more than three years. The initial 
prescriber was a GP in 61.7% of cases and a psychiatrist in the other 38.3%. 
The majority of respondents (70.5%) were women. Respondents’ ages ranged from 18 to 
78 and averaged 45.1 (s.d. 13.5), with no gender difference. Half (50.7%) were employed; 
14.8% were unemployed; 7.3% were students; and 27.2% ticked ‘other’.  The most common 
responses to the open question ‘What ethnicity or cultural group do you most identify with?’ 
were: ‘White’ or ‘Caucasian’ (47.9%), ‘Australian’ (21.8%), ‘British’/’English’/’Anglo’ 
(12.3%), ‘European’ (8.0%), ‘New Zealander’ (3.0%) and ‘Asian’ (1.5%).   
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IP addresses showed that the 1,517 respondents lived in 38 countries, most commonly 
Australia (667; 44.0%) (from where the survey was conducted), the UK (277; 18.3%), and 
the USA (247: 16.3%). The nine other countries with more than 10 respondents were: New 
Zealand (61), Germany (48), Denmark (31), Canada (30), Ireland (29), the Netherlands (24), 
Norway (19), South Africa (18) and Sweden (14). The following 26 countries contributed 
between one and seven respondents: Albania, Algeria, Austria, Belgium, Bosnia, Bulgaria, 
Croatia, Czechia, Estonia, Faroe Islands, Finland, France, Greece, Iceland, India, Italy, Israel, 
Lithuania, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Switzerland, Ukraine.  
    Most participants (1283; 84.6%) replied ‘Yes’ to ‘Do you think you were prescribed anti-
depressant medication to treat depression?’ Of the 485 who reported their primary diagnosis, 
the most commonly reported diagnoses were: Depression - 30.1%; Bi-Polar Disorder - 
21.6%; Schizophrenia spectrum disorders - 19.9%: Personality Disorders - 8.7%; Post 
Traumatic Stress Disorder - 3.5%, and Anxiety Disorders - 2.6%.  
Although the focus of this article is the adverse effects of ADs, the respondents’ views on 
whether the drugs were helpful are important characteristics of the sample. Positive outcome 
was assessed with two questions: (i) ‘As a result of taking antidepressants, my depression 
was . . . . ’ and (ii) ‘When taking antidepressants my quality of life is  . . . . ’ each followed by 
a five point multiple choice scale. Table 1 shows that about two thirds 65.2%) thought the 
drugs reduced their depression (‘greatly’ or slightly’), while 14.5% reported that they made 
the depression worse (‘slightly’ or ‘a lot’).  Similarly 60.9% reported that their Quality of 
Life was ‘improved’, while 21.2% thought it was made ‘worse’. 
 
Table 1.   Perceived efficacy of antidepressant medication.  
 
‘As a result of ADs my 
depression was…..’ 
 
Greatly 
reduced 
 
Slightly 
reduced 
 
 
Unchanged 
 
Slightly 
worse 
 
 
A lot worse 
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(n = 1475) 29.9% 35.3% 20.3% 4.9% 9.6% 
 
‘As a result of ADs my 
quality of life was…..’ 
 
Greatly 
improved 
 
Slightly 
improved 
 
 
Unchanged 
 
Slightly 
worse 
 
 
A lot worse 
(n = 1488) 24.7% 36.2% 17.9% 7.7% 13.5% 
 
 
3.2. Total Adverse Effects 
The side effects section was completed by 1,431 respondents. Nearly all (97.3%) reported 
at least one of the 20 side effects; with 83.3% reporting five or more, and 61.2% reporting ten 
or more. The mean number of adverse effects per respondent was 11.22 (s.d. 5.85). 
Participants reported an average of 3.02 (s.d. 4.02) of the effects at the ‘severe’ ‘level. Table 
2 shows that 16 of the 20 side effects listed in the questionnaire were reported by more than 
half the respondents, most commonly: ‘Feeling emotionally numb’ (70.6%), ‘Feeling foggy 
or detached’ (70.0%); ‘Feeling not like myself’ (66.2%), ‘Sexual difficulties’ (66.1%), 
‘Drowsiness’ (62.7%),  and ‘Reduction in positive feelings’ (60.4%).  
The mean Total Adverse Effects (TAE) score was 21.02 (s.d.14.12).  
 
3.3. The Antidepressants and Antipsychotics Group 
The 499 respondents who had taken both ADs and APs (AD+AP) were younger (X = 42.8 
years) than those who had only taken ADs (46.3 years), (t = 4.84. df = 1049.8, p < .0001); but 
this was unrelated to gender. 
Of the 499, 478 completed the side effects section of the questionnaire. This AD+AP 
group reported a significantly greater mean number of symptoms (12.87) than the AD only 
group (10.39) (t = 4.55, df 934.1, p < .0001). The TAE mean of the AD+AP group (25.84, 
s.d.14.56) was also significantly greater than the AD only group (18.60, s.d.13.29) (t = 9.16, 
df 885.4, p < .0001). Table 2 shows that the AD+AP respondents had experienced each of the 
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20 effects to a significantly greater degree than the AD only group.  The largest difference 
was for Suicidality, which was reported by 65.9% of the AD+AP group (24.7% at the severe 
level) compared to 42.5% of the AD only group (10.3% severe).  
 
Table 2 .  Percentages reporting each of 20 adverse effects, with and without 
antipsychotics. 
 
 Total 
sample 
(n = 1431) 
 
ADs only 
(n = 953) 
 
ADs + APs 
(n = 478) 
Feeling emotionally numb 70.6 66.1 
 
79.7 *** 
Feeling foggy or detached 70.0 65.1 
 
79.7 *** 
Feeling not like myself 66.2 61.4 
 
75.9 *** 
Sexual difficulties 66.1 64.2 
 
     69.9* 
Drowsiness 62.7 59.6 
 
68.8 *** 
Reduction in positive feelings 60.4 55.2 
 
70.9 *** 
Weight gain  60.1 55.8 
 
68.6 *** 
Dry mouth 59.3 54.6 
 
68.6 *** 
Distorted dreams 59.2 55.7 
 
66.1 *** 
Withdrawal effects 58.9 55.4 
 
65.9 *** 
Agitation  58.0 52.9 
 
68.2 *** 
Insomnia 57.7 55.7 
 
61.5 *** 
Caring less about others 54.5 49.9 
 
63.6 *** 
Dizziness 51.6 47.5 
 
59.8 *** 
Headaches 50.4 47.1 
 
56.9 *** 
Suicidality 50.3 42.5 
 
65.9 *** 
Nausea 46.8 43.3 
 
53.8 *** 
Feeling aggressive 41.0 37.6 
 
47.9 *** 
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Addiction 40.5 36.8 
 
47.7 ** 
Tremors 37.4 32.3 
 
47.5 *** 
 
Total Adverse Effects (TAE) a 
 
 
21.02 
 
18.60 
 
25.84 *** 
Mean number of adverse effects b 
 
11.22 10.39 12.87 *** 
 
a = range 0-60 
b = range 0-20 
* < 01; ** < .001; *** .0001 (greater than ADs only group) 
 
 
3.4 The Antidepressant Only Group 
In order to reduce potential contamination of the rates of the side effects by the influence 
of APs, and so as to facilitate comparisons with the largest similar survey to date, in New 
Zealand [18], the findings for the 1,018 people who had taken ADs but not APs are presented 
separately. They are then analysed, like the New Zealand survey, in terms of gender, age and 
duration of treatment.  
Of these 1,018 people, 953 completed the side effects section of the survey (see Tables 2 
and 3). The mean number of adverse effects in this group was 10.39 (s.d. 5.83), and the mean 
TAE score was 18.60 (s.d. 13.29). Most (97.0%) reported at least one of the 20 side effects; 
with 80.3% reporting five or more, and 54.7% reporting ten or more. The mean number of 
adverse effects per respondent was 10.39 (s.d. 5.83). Table 2 shows that 12 of the 20 side 
effects listed in the questionnaire were reported by more than half the respondents, most 
commonly: ‘Feeling emotionally numb’ (66.1%), ‘Feeling foggy or detached’ (65.1%), 
‘Sexual difficulties’ (64.2%) and ‘Feeling not like myself’ (61.4%). The mean Total Adverse 
Effects (TAE) score was 18.60 (s.d.13.29).  
 
3.4.1. Gender 
14 
 
Gender was related to neither mean number of adverse effects nor TAE mean scores. 
Table 3 shows, however, that two of the 20 specific adverse effects were reported to a greater 
degree by men: Sexual difficulties and Caring less about others (both at the p < .01 level). For 
example 58.2% of the men reported Caring less about others, compared to 46.6% of the 
women. 
 
3.4.2. Age 
Age was negatively correlated with number of adverse events (rho = .18, p < .0001) and to 
TAE (rho = .10, p < .0001). Age was significantly negatively correlated to eleven individual 
adverse effects, (nine at the p < .0001 level; see Table 3), most strongly with Nausea and 
Feeling emotionally numb. Age was positively related only to Dry mouth (p < .001). 
 
3.4.3. Treatment duration 
The 549 who had taken ADs for more than three years reported a significantly higher 
number of adverse effects (10.80) than the 404 who had taken them for three years or less 
(9.81) (t = 2.60, df 950, p < .01), and a higher TAE mean (19.75 vs. 17.01) (t = 3.16, df 950, 
p < .01). Table 3 shows that five adverse effects were reported at a higher level by the group 
on ADs for more than three years (all at the p < .0001 level), with the biggest differences 
being for Addiction, Withdrawal effects and Weight Gain. For example, 26.5% of those on 
ADs for three years or less reported Addiction to ADs (10.3% severe),compared to 44.5% of 
those on them for over three years (19.9% severe).  
 
Table 3.   Percentages of respondents who took only antidepressants reporting each of 
20 adverse effects, analysed by gender, age and treatment duration (more than three 
years vs. three years or less); with findings of the 2014 New Zealand survey in brackets. 
 
n = 953 % %   treatment 
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any severe gender age duration 
Feeling emotionally numb 66.1 
(60.4) 
18.2 
(13.5) 
 Y*** 
Y*** 
 
Feeling foggy or detached 65.1 
(-) 
16.3 
(-) 
 Y***  
Sexual difficulties 64.2 
(62.3) 
20.0 
(14.1) 
M* 
M** 
 >3yrs*** 
>3yrs** 
Feeling not like myself 61.4 
(52.4) 
16.7 
(11.0) 
 Y*** 
Y*** 
 
<3yrs* 
Drowsiness 59.6 
(57.8) 
10.3 
(8.6) 
  
Y*** 
 
Weight gain  55.8 
(56.4) 
14.0 
(12.2) 
 
F* 
 >3yrs*** 
>3yrs*** 
Insomnia 55.7 
(-) 
11.4 
(-) 
   
Distorted dreams 55.7 
(-) 
11.0 
(-) 
   
Withdrawal effects 55.4 
(54.9) 
23.8 
(25.0) 
 Y*** >3yrs*** 
>3yrs*** 
Reduction in positive feelings 55.2 
(41.7) 
13.2 
(8.0) 
 
M* 
  
Agitation  52.9 
(46.9) 
9.2 
(7.0) 
 Y** 
Y*** 
 
Dry mouth 54.6 
(57.6) 
10.7 
(9.7) 
 O*** >3yrs*** 
>3yrs** 
Caring less about others 49.9 
(38.8) 
11.0 
4.9 
M* 
M*** 
  
Dizziness 47.5 
(45.2) 
6.3 
(4.8) 
 Y*** 
Y*** 
 
Headaches 47.1 
(47.0) 
6.4 
(5.1) 
 Y* 
Y*** 
 
Nausea 43.3 
(39.4) 
5.1 
(4.6) 
 Y*** 
Y*** 
 
Suicidality 42.5 
(38.9) 
10.5 
(7.8) 
 Y*** 
Y*** 
 
>3yrs* 
Feeling aggressive 37.6 
(28.0) 
7.1 
(4.9) 
 
M* 
Y***  
Addiction 36.8 
(27.4) 
13.4 
(6.2) 
  >3yrs*** 
>3yrs*** 
Tremors 32.3 
(31.3) 
4.8 
(4.5) 
   
 
* < 01; ** < .001; *** .0001  
Age: spearman rank correlations (Y = younger age; O = older age) 
Gender and Treatment Duration: t-test independent means    
(-) = this variable not included in New Zealand survey 
 
 
 
16 
 
3.5. Medication Types 
Of the 1151 in the total sample who identified their AD, the most frequently named were: 
fluoxetine 223, 19.4%; sertraline 175, 15.2%; citalopram 157, 13.6%; paroxetine 112, 9.7%; 
venlafaxine 112, 9.7%; and escitalopram 93, 8.1%. There were also 126 cases of tricyclic 
ADs (10.9%), mostly amitriptyline. Fifty one (4.4%) responded in ways that indicated use of 
multiple ADS (e.g. ‘lots’, ‘various’, ‘Lost count of how many different ones’). 
Table 4 shows that there were no significant differences between the types of drugs in 
terms of the mean number of adverse effects. Citalopram, however, produced a lower mean 
TAE score than paroxetine, fluoxetine and tricyclics, all at the p < .01 level. For example: the 
mean TAE for citalopram (18.14) was significantly lower than the mean for paroxetine 
(23.44); t = 3.15, df = 250, p < .01. Citalopram’s TAE mean was also lower than the mean for 
the other six drug types combined (21.21); t = 2.85, df = 233.1, p < .01. More specifically 
citalopram produced significantly lower means for Suicidality, Caring less about others, 
Reduction in positive feelings and Feeling aggressive (all at the p < .01 level or beyond), with 
the biggest difference being for Caring less about others; t = 3.63, df = 231.3, p <  .0001.   
Table 4 also shows that usage of multiple ADs produced both a significantly higher TAE 
mean (p < .0001) and a higher mean number of adverse effects (p < .01) than all seven 
individual drug types combined. (Use of multiple ADs was unrelated to age and gender). 
       
Table 4.   Total Adverse Effects scores, and number of adverse effects, by medication 
type. 
  
n 
Mean ‘Total Adverse 
Effects’ score  
(and S.D.) 
Mean number of 
adverse effects 
(and S.D.) 
Paroxetine 102 23.44   (14.88) 11.83  (5.90) 
Fluoxetine 205 22.25  (14.38) 11.55  (5.74) 
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Tricyclics 115 22.79  (15.17)  11.53  (5.91)  
Escitalopram 90 20.32  (14.80) 11.09  (6.05)  
Venlafaxine 104 21.59  (15.07) 11.02  (5.95) 
Sertraline 171 19.18  (12.90) 10.51  (5.31) 
Citalopram 150     18.14 a,b   (11.73) 10.27 (5.52)   
    
Multiple ADs 51 28.71 c  (14.80) 13.49 d  (5.48) 
 
a. Lower than Paroxetine, Fluoxetine, and Tricyclics (p < .01) 
b. Lower than the six other individual drug types combined (p < .01) 
c. Higher than the seven drug types combined (p < .0001)  
d. Higher than the seven drug types combined (p < .01) 
 
3.6. Suicidality 
Suicidality was reported to be a side effect of taking ADs by 50.3% of the total sample, 
42.5% of the AD only group, and 65.9% of the AD+AP group. The percentages reporting 
‘severe’ suicidality were 15.1%, 10.3%, and 24.7% respectively. Suicidality was negatively 
correlated with age (rho = .12, p < .0001), but was not related to gender. The specific adverse 
effects most strongly correlated with Suicidality were: Feeling not like self (rho = .58), 
Reduction in positive feelings (rho = .58) and Feeling aggressive (rho = .54) (all p < .0001). 
(The specific tests reported here are for the AD only group, but the findings were very similar 
for the AD+AP group and the sample as a whole).  
Citalopram was significantly less likely than the other drugs combined to lead to 
suicidality (t = 2.53, df = 236.3, p < .0001). Both forms of polypharmacy significantly 
increased the rate of suicidality: multiple ADs (t = 3.38, df 1072, p < .001), and APs in 
addition to ADs (t = 9.92, df 837.3, p < .0001).  
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3.7. Information about Adverse Effects 
In response to ‘Did the doctor inform you of any possible side effects?’ 520 (34.3%) 
replied Yes, 973 (64.1%) said No, and 24 (1.6%) did not reply. Being informed was unrelated 
to age or gender, or to whether the prescriber was a GP or a Psychiatrist.  
Those who had been informed about side effects reported fewer adverse effects on average 
(9.75) than those not informed (12.01) (t = 7.07; df = 1422, p < .0001); and also produced a 
lower TAE mean (36.71 vs 43.36; t = 8.69, df = 11180.9, p < .0001). Every one of the 20 side 
effects was reported to a significantly greater extent by people who had not been informed 
about side effects (18 at the p < .0001 level).  
Of the 520 who recalled being told about side effects, 371 (71.3%) recalled one or more 
specific side effects they had been told about (see Table 5), most frequently Nausea (77) and 
Weight changes (75).  A further 21 referred to a written list of effects being given, or read, to 
them. 
 
Table 5.   Frequency of adverse effects about which participants had been informed (6 
or more). 
Nausea/vomiting 77 Increased depression 22 
Weight/appetite changes 75 Anxiety 17 
Sleepiness/drowsiness/sedation 56 Mania/mood swings 10 
Dry mouth  51 Withdrawal symptoms/addiction 9 
Sexual dysfunction 42 Constipation 8 
Suicidality 35 Tremors 8 
Insomnia 22 Agitation/restlessness 8 
Dizziness 26 Loss of interest, emotions/lethargic 8 
Headaches 22 Blurred vision  6 
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4. DISCUSSION 
This study confirms previous studies that have found that when AD users are asked 
directly they report an extensive range of adverse effects at very high frequencies. Thus this 
kind of survey can be a valuable adjunct to more traditional methodologies for assessing 
adverse drug effects, as can spontaneous reporting systems [24] and real-world data gathered 
from clinical practice [25]. 
Sixteen effects were experienced by more than half of the total sample. Amongst those 
who had only taken ADs the rates are slightly higher than those found in in the earlier New 
Zealand survey [18], but are quite similar overall. For example Feeling emotionally numb 
was reported by 66.1% in the current study and 60.4% in the New Zealand study.  
Furthermore, the three side effects introduced to the current study because of spontaneous 
reporting in the New Zealand study all produced very high response rates: Feeling foggy or 
detached (65.1%), Insomnia (55.7%) and Distorted dreams (55.7%) (see Table 3). 
The second major finding is the confirmation of very high rates of adverse effects in the 
emotional and interpersonal domains [12-17]. In both the current international study and the 
earlier New Zealand survey [18] Emotional numbing, Sexual difficulties, Feeling not like 
myself, Reduction in positive feelings and Caring less about others were extremely common. 
Similarly, a UK online survey of over 1,000 AD users [26] found that 60% reported negative 
effects in at least one of the five interpersonal domains assessed (most commonly ‘Sex life’ 
and ‘Work or study’). A recent examination of over 3,000 online comments by AD users 
found that ‘Emotional and behavioral’ adverse effects were reported far more than 
biological/medical effects such as Cardiovascular, Gastrointestinal or Metabolic [27]. All 
20 
 
these findings contrast with more traditional studies of adverse effects, such as drug trials 
which have focussed, like most officially sanctioned checklists, on the adverse 
biological/medical effects [9-11].   
There was some consistency between the New Zealand and current study in terms of 
gender and age. In both studies men were more likely than women to report Sexual 
difficulties and Caring less about others. In both studies younger people reported more 
adverse effects overall, particularly for Feeling emotionally numb, Feeling not like myself, 
Suicidality, Dizziness, and Nausea. 
 
4.1. Polypharmacy   
Presenting the rates of adverse effects for those taking only ADs is a sensible way to try to 
ensure that the reported effects are caused specifically by ADs. They underestimate, however, 
rates in the real world, where it is commonplace for people to be on multiple types of 
psychiatric medication [28, 29]. Therefore the rates for the total sample in the current study 
may be the most accurate account of the adverse effects being experienced by AD users. The 
finding that every one of the 20 adverse effects was significantly more common amongst 
those who took both ADs and APs than among those who took only ADs is important. The 
interactive negative effects of different types of psychiatric drugs is rarely studied in 
traditional drug trials. 
In the UK survey of over 1,000 AD users [26] more than half were taking one or more 
additional psychiatric drugs. The number of types of medication correlated with overall 
severity of side effects. The number of medication types was also related to each of the six 
specific types of adverse effect. For example, while 44% of those on antidepressants alone 
reported an adverse effect on their sex life, this was the case for 54% of those on 
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antidepressants plus one other psychiatric medication, and 63% of those on three additional 
medications. A 2013 review [28] concluded: 
While evidence for the added benefit of psychiatric polypharmacy is limited, there is 
growing evidence regarding the increased adverse effects associated with such 
combinations.   
In the current study, three specific adverse effects were reported by three out of every four 
of the participants who took both ADs and APs: Feeling emotionally numb, Feeling foggy or 
detached, and Feeling not like myself.  
 
4.2. Suicidality 
Since the 1990s studies have documented that ADs increase suicidality for a small number 
of people [30, 31]. Asking AD users directly, however, suggests that the problem may be far 
greater than originally thought. In the current study ‘suicidality’… ‘as a result of taking the 
antidepressant’ was reported by 42.5% of the AD only group. This corroborates the 38.9% 
finding in the large New Zealand survey [18]. The rates at the ‘severe’ level of suicidality 
were 10.5% and 7.8% respectively. In both studies the likelihood of experiencing suicidality 
increased the longer the person stayed on the ADs. Furthermore, nearly two in every three 
people (65.9%) taking both ADs and APs reported suicidality (24.7% at the ‘severe’ level). 
The other form of polypharmacy, multiple ADs, also increased risk of suicide compared to 
taking just one AD.  
Increased suicidality as a result of ADs is especially strong in children, adolescents and 
young adults [32, 33], leading the F.D.A. to place a ‘Black Box’ warning, in 2006, on all ADs 
for people under the age of 26 [32]. The current study excluded children but, like the New 
Zealand survey, confirmed that younger adults are indeed even more likely to report 
suicidality than older adults.  
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4.3. Withdrawal Effects and Addiction 
More than half of participants taking only ADs (55.4%) reported Withdrawal effects 
(23.8% at the ‘severe’ level). This is consistent with the 54.9% in the New Zealand survey 
[18]. Furthermore, about a third reported Addiction in both studies (36.8% and 27.4% 
respectively). In both studies both Addiction and Withdrawal effects were, unsurprisingly 
perhaps, reported significantly more by people who had been on ADs for more than three 
years. For example, in the New Zealand study 74% of those on ADs for more than three years 
reported Withdrawal symptoms, and 46% of those reporting the symptoms described them as 
‘severe’ [34]. A recent Dutch study found that of 692 users of tapering strips 671 (97%) had 
experienced some level of withdrawal effects when they had previously tryed to stop their 
ADs; and that 339 of those 671 (51%) reported the severity of the withdrawal as 7 on a 7 
point scale [35].  
The issue of whether ADs should be considered addictive has polarised opinion. In a 
survey of over 2,000 members of the British public, many of whom of course were either 
taking ADs or knew people who were taking them, 78% described ADs as addictive [36]. 
The Diagnostic and Statistical Manual for Mental Disorders [37] requires that two of eleven 
criteria are met for ‘substance dependence’. The current study and the large New Zealand 
survey [18] indicate that ADs may meet at least four of these criteria for many people: 
‘Withdrawal manifesting as a characteristic syndrome’, ‘Wanting to cut down or quit but not 
being able to do it’, ‘Continued use despite persistent or recurring social or interpersonal 
problems caused or made worse by substance use’ and ‘Stopping or reducing important 
social, occupational, or recreational activities due to substance use.’ 
Nevertheless, the only reference to the issue in the American Psychiatric Association 
Practice Guideline for depression is ‘Common misperceptions about antidepressants (e.g. 
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they are addictive) should be clarified’ [38]. (The authors listed, between them, over 80 
instances of receiving payments from drug companies). In the UK the Royal College of 
Psychiatrists (R.C.P.) states: ‘We would like to reassure readers that despite some people 
having symptoms of withdrawal when stopping antidepressants, antidepressants are not 
addictive’ [39]. In February, 2018 the President of the R.C.P. and the Chair of its 
Psychopharmacology Committee jointly informed the public that  ‘We know that in the vast 
majority of patients, any unpleasant symptoms experienced on discontinuing antidepressants 
have resolved within two weeks of stopping treatment’ [40]. 
The term ‘Discontinuation Syndrome’ was introduced in 1996, at a ‘closed symposium’ in 
Phoenix, Arizona [41]. The gathering was funded by Eli Lilly. The ‘Discontinuation 
Consensus Panel’ consisted of industry funded professionals who argued that AD withdrawal 
is very different from withdrawal from benzodiazepines. 
Researchers at the Nordic Cochrane Centre disagree with the A.P.A, the R.C.P, and Eli 
Lilly spokespersons. Their 2012 review [42] of 45 papers on benzodiazepines and 31 papers 
on SSRIs concluded that ‘Withdrawal reactions to SSRIs appear to be similar to those for 
benzodiazepines; referring to these reactions as part of a dependence syndrome in the case of 
benzodiazepines, but not selective serotonin re-uptake inhibitors, does not seem rational’.  
The disputes seem to rest primarily on disagreements about the definition of ‘addiction’. 
An approach which circumvents these disagreements is to allow people who have taken ADs 
to interpret the term ‘addiction’ as they wish, thereby respecting their actual personal 
experience.  A 2004 review of studies of ‘Patients’ preferences in the treatment of depressive 
disorder in primary care’ found that ‘Antidepressants were often regarded as addictive’ [43]. 
A 2014 review [12], of studies of ‘Patient-centred perspectives on antidepressant use’, 
concurred, reporting that ‘the most frequently mentioned reason for a negative opinion of 
antidepressants is that they may be addictive’. High rates of addiction and withdrawal effects 
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among AD users, when asked directly, have been found in Denmark [44], the Netherlands 
[35, 45], Scotland [46] and the USA [13, 47]. A 2012 survey by the Royal College of 
Psychiatrists in the UK found that of 817 people who had stopped taking ADs, 63% 
experienced withdrawal symptoms [48]. 
High rates of addiction and difficulties withdrawing are consistent with findings that the 
ever increasing prescription rates of ADs are not explicable in terms of increased incidence of 
depression, or changes in help-seeking behavior [49], but rather in terms of increases in 
repeat prescriptions. A study of 189,851 GP patients in the UK found that a doubling of 
prescribing over eight years was explained not by increases in new prescriptions but by a 
doubling of the number of prescriptions per patient [50]. 
 
4.4. Information 
In the current study only one third of AD users (34%) recalled being told about any side  
effects. This is lower than the 64% in the New Zealand survey and the findings of two British 
studies, 59% [51] and 55% [52]. Together, these four studies suggest that between one and 
two thirds of AD recipients are told nothing about side effects. What information that is 
imparted seems to focus on biological side effects. In both the current study and the New 
Zealand study [53] the side effects that people were most commonly warned about were 
nausea and weight gain. Less than five percent were warned about increased suicidality in 
either study. None were told about feeling less like themselves or about possible effects on 
their relationships with others (other than sexual dysfunction). In both studies fewer than two 
percent were told anything about withdrawal effects [53]. This breaches the fundamental 
ethical principle of ‘informed consent’ which is binding on all health professionals. 
 
4.5. Strengths and Limitations 
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This is a self selected, convenience sample, despite being the second largest sample ever 
directly surveyed. Although it is more international than the original New Zealand based 
survey, almost the entire sample lived in Europe, North America or Australasia. The over 
representation of women (70.5%) is less of an issue as women are prescribed ADs 
approximately twice as often as men. The very high rates of adverse effects raises the 
possibility that the sample is biased towards people who had found ADs ineffective and 
therefore may have had ‘an axe to grind’. However, two thirds (65.2%) reported that the ADs 
had reduced their depression. The study relies on self-report, but so do most traditional 
studies of the effects of drugs, positive and negative. The fact that some of the reports are for 
events many years previously is more of a problem. For example, some participants may 
actually have been given more information about adverse effects than they could recall years 
later. 
The failure to gather data about the duration of withdrawal effects is also a limitation. A 
recent review [54] found that they typically ‘last a few weeks’ but identified ‘many 
variations… including longer persistence of disturbances’ and two studies documenting 
withdrawal symptoms up to one year following paroxetine discontinuation. More research is 
urgently needed in this area.  
It is possible that some respondents may not have taken ADs and may be responding on 
behalf of a loved one or may even have, for some unknown reason, fabricated a set of 
responses.  Safeguards were in place, however, against repeat responders and people who 
mistakenly thought their drug was an AD when it was not (see Methods). Finally, the study 
did not allow for possible confounding variables such as substance abuse and other medicines 
besides APs. 
 
 
26 
 
5. CONCLUSION 
As noted earlier, the experience of patients is finally receiving the attention it so obviously 
warrants. Directly surveying patients, and using PROMs, helps to ‘ensure that research is 
both robust and of maximum value for the use of medicinal products, therapy, or health 
services’. . . . and ‘reflects the ongoing health service commitment of involving patients and 
the public within the wider context of the development and evaluation of health care service 
delivery and quality improvement.’ [19, p.61] 
Asking people directly about their experience of ADs reveals that their adverse effects 
may be far more varied and prevalent and damaging than previously realised when relying on 
more traditional research methodologies. Together with the consistent findings that ADs are 
no more effective than placebo for many recipients, the findings of these recent direct-to-
consumer surveys produce a cost-benefit analysis that cannot justify the current 
extraordinarily high prescription rates of ADs. A first step towards reducing inappropriate 
prescribing would be for all prescribers to fully inform all potential recipients of all potential 
side effects, including suicidality, emotional blunting and withdrawal effects. Psychiatric 
polypharmacy should be a last resort rather than standard practice. It seems that health 
services need to challenge the denial and minimization of the drug companies and some 
professional bodies and urgently develop drug withdrawal services for the millions already 
trying to come off these drugs but experiencing withdrawal effects which are sometimes 
severe and protracted.  
 
CONFLICT OF INTEREST 
Both authors declare no financial, personal or potential conflicts of interest. 
 
 
27 
 
REFERENCES 
[1] Ilyas S, Moncrieff J. Trends in prescriptions and costs of drugs for mental disorders in 
England, 1998 −2010. Br J Psychiatry 2012; 200: 393-8. 
[2]  Kantor E, Rehm C, Haas J, Chan A, Giovannucci E. Trends in prescription drug use among 
adults in the United States from 1999–2012. J Am Med Assoc 2015; 314: 1818-30. 
[3]  NHS Digital. Prescriptions dispensed in the community 2006-2016. London: National Health 
Service; 2017. 
[4]  Khan A, Brown W. Antidepressants versus placebo in major depression: an overview. World 
Psychiatry 2015; 14: 294-300. 
[5]  Khan A, Khan S, Brown W. Are placebo controls necessary to test new antidepressants and 
anxiolytics? Int J Neuropsychopharmacol 2002; 5: 193-7. 
[6]  Moncrieff J. Antidepressants: misnamed and misrepresented. World Psychiatry 2015; 14: 
302-3. 
[7]  Kirsch I, Deacon B, Huedo-Medina T, et al. Initial severity and antidepressant benefits: a 
meta-analysis of data submitted to the Food and Drug Administration. PLOS Med 2008; 
20085: 260-8. 
[8]  Cipriani A, Furukawa T, Salanti G., et al. Comparative efficacy and acceptability of 21 
antidepressant drugs for the acute treatment of adults with major depressive disorder: a 
systematic review and network meta-analysis. Lancet 2018; 391: 1357-66. 
[9]  Jakobsen J, Katakam K, Schou A, et al. Selective serotonin reuptake inhibitors versus placebo 
in patients with major depressive disorder. A systematic review with meta-analysis and Trial 
Sequential Analysis. BMC Psychiatry 2017; 17: 58.  
[10]  Uher R, Farmer A, Henigsberg N, et al. Adverse reactions to antidepressants. Br J Psychiatry 
2009; 195: 202-10. 
[11]  Adkins D, Clark S, Åberg K, et al. Genome-wide pharmacogenomic study of citalopram-
induced side effects in STAR*D. Transl Psychiatry 2012;  2: e129.  
28 
 
[12]  Gibson K, Cartwright C, Read J. Patient-centred perspectives on antidepressant use: a 
narrative review. Int J Ment Health Nurs 2014; 43: 81-99. 
[13]  Givens J, Datto C, Ruckdeschel K, et al. Older patients' aversion to antidepressants. J General 
Intern Med 2006; 21: 146-51. 
[14]  Goldsmith L, Moncrieff J. The psychoactive effects of antidepressants and their association 
with suicidality. Curr Drug Saf 2011; 6: 1-7. 
[15]  Liebert R, Gavey N. ‘I Didn't Just Cross a Line I Tripped Over an Edge’: experiences of 
serious adverse effects with selective serotonin reuptake inhibitors. NZ J Psychol 2008; 7: 38-
48. 
[16]  Pestello F, Davis-Berman J. Taking anti-depressant medication: a qualitative examination of 
internet postings. J Ment Health 2008; 17: 349-60. 
[17]  Price J, Cole V, Goodwin G. Emotional side-effects of selective serotonin reuptake  
 inhibitors: qualitative study. Br J Psychiatry 2009; 195: 211-217. 
[18]  Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 
1,829 New Zealanders while taking antidepressants. Psychiatry Res 2014; 216: 67-73. 
[19] Weldring T, Smith, S. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome 
Measures (PROMs). Health Serv Insights 2013; 6: 61-8.  
[20] Krägeloh C,  Czuba K, Billington R, Kersten P, Siegert R. Using feedback from Patient-
Reported Outcome Measures in mental health services: A scoping study and typology. 
Psychiatr Serv 2015; 66: 224-41. 
[21]  Gibson K Cartwright C, Read, J. ‘In my life antidepressants have been….’ :  a qualitative 
analysis of users’ diverse experiences of antidepressants. BMC Psychiatry 2016; 16: 135. 
[22]  Read J, Gibson K, Cartwright C, Shiels C, Dowrick C, Gabbay M. The nonpharmacological 
correlates of self-reported efficacy of antidepressants. Acta Psychiatr Scand 2015; 131: 434-
45. 
[23]  Read J, Gibson K, Cartwright C, Shiels C, Magliano L. Beliefs of people taking  
 antidepressants about the causes of their own depression. J Affect Dis 2015; 174: 150-6. 
29 
 
[24]  Kim S, Park K, Kim M, Yang B, Choi H, Park B. Data-mining for detecting signals of 
adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System 
(KAERS) database. Psychiatry Res 2017; 256: 237-42. 
[25] Degli Esposti L, Piccinni C, Sangiorgi D, Fagiolini A, Buda S. Patterns of antidepressant use 
in Italy: therapy duration, adherence and switching. Clin Drug Investig 2015; 35: 735-42. 
[26] Read J, Gee A, Diggle J, Butler H. The interpersonal adverse effects reported by 1,008 users 
of antidepressants; and the incremental impact of polypharmacy. Psychiatry Res 2017; 256: 
423-7. 
[27]  Hughes S, Lacasse J, Fuller R, Spaulding-Givens J. Adverse effects and treatment satisfaction 
among online users of four antidepressants. Psychiatry Res 2017; 255: 78-86. 
[28]  Kukreja S, Kalra G, Shah N, Shrivastava A. Polypharmacy in psychiatry: a review. Mens 
Sana Monogr 2013; 11: 82–99. 
[29]  Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-
based psychiatry. Arch Gen. Psychiatry 2010; 67: 26-36. 
[30]  Makris G, Reutfors J, Ösby U, et al. Suicide seasonality and antidepressants: a register-based 
study in Sweden. Acta Psychiatr Scand 2013; 127: 117-25. 
[31]  Nassir G, Vohringer P, Whitham E. Antidepressants from a public health perspective: re-
examining effectiveness, suicide, and carcinogenicity. Acta Psychiatr Scand 2013; 127: 893. 
[32]  Food and Drug Administration. Clinical review: relationship between antidepressant drugs 
and suicidality in adults, 2006. www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-
FDA.pdf.  [accessed Feb 2018]. 
[33]  Hammad T, Laughren T, Racoosin J. Suicidality in pediatric patients treated with 
antidepressant drugs. Arch Gen Psychiatry 2006; 63: 332-9. 
[34]  Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: patient 
perspectives of benefits and adverse effects. Patient Pref Adher 2016; 10: 1401-7. 
30 
 
[35]  Van Os J, Groot P. 2018. Antidepressant tapering strips to help people come off medication 
more safely. Psychosis Psychol Soc Integrative Approaches, 
doi.org/10.1080/17522439.2018.1469163 
[36]  Priest R, Vize C, Tylee A.  Lay people’s attitudes to treatment of depression. BMJ 1996; 313: 
858-9.  
[37]  American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th 
ed. Washington D.C.: A.P.A.; 2013. 
[38]  American Psychiatric Association. Practice guideline for the treatment of patients with major 
depressive disorder. 3rd ed. Washington D.C.: A.P.A.; 2010. 
[39]  Royal College of Psychiatrists. Antidepressants. London: R.C.P.; 2015 
www.rcpsych.ac.uk/health/advice/treatmentswellbeing/antidepressants.aspx.  [accessed Feb 
2018]. 
[40] Burns W, Baldwin D. (2018). Letter to the editor. The Times; Feb. 24. 
[41]  Schatzberg A, Haddad P, Kaplan E. et al. Seretonin Reuptake Inhibitor Discontinuation 
Symndrome: a hypothetical defintion. Discontinuation Consensus Panel. J Clin Psychiatry 
1997; 58 (suppl 7): 5-10. 
[42]  Nielsen M, Hansen E, Gøtzsche P. What is the difference between dependence and 
withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake 
inhibitors. Addict 2012; 107: 900-08. 
[43]  van Schaik D,  Klijnb A, van Hout H, van Marwijk H, Beekman A, van Dyck R. Patients’ 
preferences in the treatment of depressive disorder in primary care.  Gen Hosp Psychiatry 
2004; 26: 184-9. 
[44]  Kessing L, Hansen H, Demyttenaere K, Bech P. Depressive and bipolar disorders: patients' 
attitudes and beliefs towards depression and antidepressants. Psychol Med 2005; 35: 1205-13. 
[45]  Hoencamp E, Stevens A, Haffmans J. Patients' attitudes toward antidepressants.  Psychiatr 
Serv 2002; 53: 1180-1.  
[46]  Stone J, Durrance D, Wojcik W, Carson A, Sharpe M. What do medical outpatients  
attending a neurology clinic think about antidepressants? J Psychosom Res 2004; 56: 293-5. 
31 
 
[47]  Bogner H, Cahill E, Frauenhoffer C, Barg F. Older primary care patient views regarding 
antidepressants: a mixed methods approach. J Ment. Health 2009; 18: 57-64. 
[48]  Royal College of Psychiatrists.  Coming off antidepressants.  London: R.C.P.; 2012. 
www.rcpsych.ac.uk/healthadvice/treatmentswellbeing/antidepressants/comingoffantidepressa
nts.aspx. [accessed Feb 2018]. 
[49]  Munoz-Arroyo R, Sutton M, Morrison J. Exploring potential explanations for the increase in 
antidepressant prescribing in Scotland using secondary analyses of routine data. Br J Gen 
Pract 2006; 56: 423-8. 
[50]  Moore M, Yuen H, Dunn N, Mullee M, Maskell J Kendrick T. Explaining the rise in  
antidepressant prescribing: a descriptive study using the general practice research database. 
Br Med J 2009; 339: b3999.  
[51]  Byng R, Bury C, Weaver L. Patients' experiences of consultations for depression and 
predictors of adherence to antidepressants. Prim Care Comm Psychiatry 2007; 12: 109-15. 
[52]  Mind. Antidepressants prescribed too quickly for too long. London; Mind; 2012. 
http://www.mind.org.uk/news/7546_antidepressants_prescribed_too_quickly_for_too_long_fi
nds_mind_survey [accessed Feb 2018]. 
[53] Read J, Cartwright C, Gibson K.  How many of 1,829 antidepressant users report withdrawal 
symptoms or addiction?  Int J Ment Health Nurs 2018, doi: 10.1111/inm.12488 
[54] Fava G, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal Symptoms after Selective 
Serotonin Reuptake Inhibitor discontinuation: a systematic review. Psychother Psychosom, 
2015; 84: 72-81. 
 
 
